Zobrazeno 1 - 10
of 153
pro vyhledávání: ''
Autor:
Pedro Iglesias, Betina Biagetti, Marta Araujo-Castro, Victoria Alcázar, Fernando Guerrero-Pérez, Noelia Rivero, Anna Casteràs, Carlos García Gómez, Belén García Izquierdo, Víctor Viedma Torres, Eider Pascual-Corrales, Isabel Pavón, Carles Villabona, Fernando Cordido, Juan J. Díez
[Abstract] Background: In recent years, dopamine agonists (DAs) have become an attractive therapeutic option to prevent both tumor growth and post-surgical tumor remnant growth in clinically non-functioning pituitary adenoma (NFPA). Aim: To analyze o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b40d967446a1fd17b7ca680578db3cc8
https://hdl.handle.net/2183/32378
https://hdl.handle.net/2183/32378
Autor:
Ryusaku Matsumoto, Masaaki Yamamoto, Genzo Iguchi, Shin Urai, Hidenori Fukuoka, Wataru Ogawa, Kentaro Suda, Hiroki Shichi, Keitaro Kanie, Yutaka Takahashi, Hironori Bando, Yasunori Fujita
Publikováno v:
Cancer Immunology, Immunotherapy
Background Immune checkpoint inhibitors (ICIs) as a cancer immunotherapy have emerged as a treatment for multiple advanced cancer types. Because of enhanced immune responses, immune-related adverse events (irAEs), including endocrinopathies such as h
Autor:
Kohei Shitara, Toshihiko Doi, Hisashi Hosaka, Peter Thuss-Patience, Armando Santoro, Federico Longo, Ozgur Ozyilkan, Irfan Cicin, David Park, Aziz Zaanan, Carles Pericay, Mustafa Özgüroğlu, Maria Alsina, Lukas Makris, Karim A. Benhadji, David H. Ilson
Publikováno v:
Scientia
Background Trifluridine and tipiracil (FTD/TPI) demonstrated survival benefit vs placebo and manageable safety in previously treated patients with metastatic gastric/gastroesophageal junction cancer (mGC/GEJC) in the randomized, placebo-controlled, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a45e883686e60f91bacc0ff8cb91867
https://hdl.handle.net/11351/8082
https://hdl.handle.net/11351/8082
Autor:
Mette-Triin Purde, Rebekka Niederer, Nikolaus B. Wagner, Stefan Diem, Fiamma Berner, Omar Hasan Ali, Dorothea Hillmann, Irina Bergamin, Markus Joerger, Martin Risch, Christoph Niederhauser, Tobias L. Lenz, Martin Früh, Lorenz Risch, David Semela, Lukas Flatz
Publikováno v:
Purde, Mette‑Triin; Niederer, Rebekka; Wagner, ikolaus B.; Diem, Stefan; Berner, Fiamma; Hasan Ali, Omar; Hillmann, Dorothea; Bergamin, Irina; Joerger, Markus; Risch, Martin; Niederhauser, Christoph; Lenz, Tobias L.; Früh, Martin; Risch, Lorenz; Semela, David; Flatz, Lukas (2022). Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. Journal of cancer research and clinical oncology, 148(3), pp. 647-656. Springer 10.1007/s00432-021-03870-6
Journal of Cancer Research and Clinical Oncology
Journal of Cancer Research and Clinical Oncology
Purpose Immune checkpoint inhibitor (ICI)-induced hepatitis belongs to the frequently occurring immune-related adverse events (irAEs), particularly with the combination therapy involving ipilimumab and nivolumab. However, predisposing factors predict
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::812bf92bad1e3210e93f155d71738545
https://boris.unibe.ch/162047/1/Purde2021_Article_PresenceOfAutoantibodiesInSeru.pdf
https://boris.unibe.ch/162047/1/Purde2021_Article_PresenceOfAutoantibodiesInSeru.pdf
Autor:
Yoshikazu Takahashi, Hidekazu Shirota, Takashi Yoshioka, Takuhiro Yamaguchi, Kota Ouchi, Michio Kuroki, Shin Takahashi, Masahiro Takahashi, Masaki Tanaka, Masanobu Takahashi, Chikashi Ishioka, Yasuhiro Sakamoto, Hideki Shimodaira, Hiroo Imai, Satoshi Kato, Keigo Komine, Kazunori Otsuka, Hiroyuki Shibata, Hisatsugu Ohori, Hiroaki Yamaguchi, Yasushi Tsuji
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The current study aimed to determine the efficacy of trifluridine/tipiracil for elderly patients with advanced colorectal cancer. Methods This single-arm, open-label, multicenter, phase II study included elderly patients aged 65 years or more
Autor:
Hamid Abdollahi, Habib Zaidi, Mathieu Hatt, Arman Rahmim, Isaac Shiri, Ghasem Hajianfar, Mehrdad Oveisi, Hasan Maleki, Saeed Ashrafinia
Publikováno v:
Molecular Imaging and Biology, Vol. 22, No 4 (2020) pp. 1132-1148
Shiri, I, Maleki, H, Hajianfar, G, Abdollahi, H, Ashrafinia, S, Hatt, M, Zaidi, H, Oveisi, M & Rahmim, A 2020, ' Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms ', Molecular Imaging and Biology, vol. 22, no. 4, pp. 1132-1148 . https://doi.org/10.1007/s11307-020-01487-8
Molecular Imaging and Biology, 22(4), 1132-1148. SPRINGER
Shiri, I, Maleki, H, Hajianfar, G, Abdollahi, H, Ashrafinia, S, Hatt, M, Zaidi, H, Oveisi, M & Rahmim, A 2020, ' Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms ', Molecular Imaging and Biology, vol. 22, no. 4, pp. 1132-1148 . https://doi.org/10.1007/s11307-020-01487-8
Molecular Imaging and Biology, 22(4), 1132-1148. SPRINGER
Aim: In the present work, we aimed to evaluate a comprehensive radiomics framework that enabled prediction of EGFR and KRAS mutation status in NSCLC cancer patients based on PET and CT multi-modalities radiomic features and machine learning (ML) algo
Autor:
Gemma Castaño-Vinyals, Mercedes Vanaclocha-Espi, Rafael Marcos-Gragera, Vicente Martín, Oscar Zurriaga, Beatriz Pérez-Gómez, Adonina Tardón, María Ederra, Jone M. Altzibar, Carmen Vidal, Ines Gomez-Acebo, Maria Sala, Pilar Amiano, Ana Molina-Barceló, Dolores Salas, Marina Pollán, Marta Hernández-García, Nuria Aragonés, Manolis Kogevinas
Publikováno v:
Repisalud
Instituto de Salud Carlos III (ISCIII)
Cancer Causes Control . 2022 Jan;33(1):125-136
Cancer Causes and Control, 2022, vol. 33, p. 125-136
Articles publicats (IdIBGi)
DUGiDocs – Universitat de Girona
instname
Scopus
RUO. Repositorio Institucional de la Universidad de Oviedo
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Cancer Causes & Control
Instituto de Salud Carlos III (ISCIII)
Cancer Causes Control . 2022 Jan;33(1):125-136
Cancer Causes and Control, 2022, vol. 33, p. 125-136
Articles publicats (IdIBGi)
DUGiDocs – Universitat de Girona
instname
Scopus
RUO. Repositorio Institucional de la Universidad de Oviedo
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Cancer Causes & Control
This research was supported by Acción Transversal del Cáncer, approved by the Spanish Council of Ministeres on the 11th October 2007, by the Carlos III Health Institute-FEDER (PI08/1770, PI08/0533, PI08/1359, PS09/00773, PS09/01286, PS09/01903, PS0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a26453b65c0b79846cf45ef18d8634b
http://hdl.handle.net/20.500.12105/14549
http://hdl.handle.net/20.500.12105/14549
Autor:
Luca Nicosia, Germana Lissidini, Manuela Sargenti, Anna Carla Bozzini, Gabriel Farante, José Vila, Chiara Oriecuia, Eleonora Pagan, Vincenzo Bagnardi, Matteo Lazzeroni, Filippo Pesapane, Claudia Sangalli, Viviana Galimberti, Enrico Cassano, Paolo Veronesi
Publikováno v:
BREAST CANCER RESEARCH AND TREATMENT
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Purpose To present an overview of the management of male patients with Ductal Carcinoma In Situ of the breast (male DCIS). Methods We retrospectively studied all male patients with a diagnosis of pure DCIS from January 1999 to December 2018: 20 patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a84bbd34cb15b26ed5839006aa50f72e
https://hdl.handle.net/10281/398262
https://hdl.handle.net/10281/398262
Autor:
Kyriakos S. Markides, Elizabeth A. Platz, Yong Fang Kuo, Mohit Khera, Danmeng Huang, M. Kristen Peek, Jacques Baillargeon, David S. Lopez, Konstantinos K. Tsilidis, Steven E. Canfield
Publikováno v:
Cancer Causes Control
Purpose: Previous studies have reported conflicting results in the associations of testosterone replacement therapy (TTh) and statins use with prostate cancer (PCa). However, the combination of these treatments with PCa stage and grade at diagnosis a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3807f5ba79c0f1d9a8dc281c47b02b3e
http://hdl.handle.net/10044/1/89954
http://hdl.handle.net/10044/1/89954
Autor:
M.T. Huizing, Stephen Chan, Stefania Russo, Gail S. Wright, Joyce Steinberg, Andrew M Wardley, Ron Bose, Robyn R. Young, A. Jo Chien, Iulia Cristina Tudor, Andrea Rocca, Lowell L. Hart, Javier Cortes, Kathy D. Miller, Hope S. Rugo, Marie-Pascale Graas, Louise Provencher, Patrick Neven, Jennifer Sugg, Ian E. Krop, David Cameron, Vandana G. Abramson
Publikováno v:
Wardley, A, Cortes, J, Provencher, L, Miller, K, Chien, A J, Rugo, H S, Steinberg, J, Sugg, J, Tudor, I C, Huizing, M, Young, R, Abramson, V, Bose, R, Hart, L, Chan, S, Cameron, D, Wright, G S, Graas, M, Neven, P, Rocca, A, Russo, S & Krop, I E 2021, ' The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer ', Breast cancer research and treatment . https://doi.org/10.1007/s10549-021-06109-7
Breast Cancer Research and Treatment
Scientia
Breast cancer research and treatment
Breast Cancer Research and Treatment
Scientia
Breast cancer research and treatment
Purpose Androgen receptor (AR) expression occurs in up to 86% of human epidermal growth factor receptor 2-positive (HER2+) breast cancers. In vitro, AR inhibitors enhance antitumor activity of trastuzumab, an anti-HER2 antibody, in trastuzumab-resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98cdcc0d199475dcadec98b642506659
https://lirias.kuleuven.be/handle/20.500.12942/705321
https://lirias.kuleuven.be/handle/20.500.12942/705321